CGTN AMERICA & CCTV UN: CMG Presents “Prelude to the Spring Festival Gala” in New York City, Celebrating the Year of the Horse
WASHINGTON, Feb. 12, 2026 /PRNewswire/ -- CGTN America & CCTV UN releases…
HABANOS, S.A. PRESENTS TRINIDAD CORCEL: AN EXCLUSIVE VITOLA TO CELEBRATE THE CHINESE NEW YEAR
Habanos, S.A. presents Trinidad Corcel, the latest addition to the Trinidad brand's…
Castrol proudly presents: Drive Me To The Moon
Castrol unveils a new documentary in collaboration with Lunar Outpost: a worldwide…
ASUS Republic of Gamers Presents Next-Gen Gaming Innovations, Commemorates 20 Years of Gaming Excellence at CES 2026
KEY POINTS Two decades of gaming leadership: At its Dare to Innovate…
Samsung Presents ‘Your Companion to AI Living’ at The First Look during CES 2026
Next-generation AI-powered devices and experiences to be showcased at the company's exclusive…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L…
